Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSCT vs Standard Therapy for Severe SLE
NCT00230035Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2005
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous CD34+ hematopoietic stem cells in systemic lupus erythematosus (SLE), sponsored by National Institute of Allergy and Infectious Diseases. Planned start Sep 2005; status: withdrawn.
02
Drugs
autologous CD34+ hematopoietic stem cells
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00230035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00230035.